Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Michelle Meyer, Eric Huang, Olga Yuzhakov, Palaniappan Ramanathan, Giuseppe Ciaramella, Alexander Bukreyev

    Research output: Contribution to journalArticle

    15 Scopus citations


    Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

    Original languageEnglish (US)
    Pages (from-to)451-455
    Number of pages5
    JournalJournal of Infectious Diseases
    Issue number3
    StatePublished - Jan 17 2018



    • antibody response
    • Ebola virus
    • immunization
    • RNA
    • vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Infectious Diseases

    Cite this